Stryker Corporation (NYSE:SYK) reported a 9% organic sales growth in Q2 2026, alongside a 17.9% increase in adjusted earnings per share, reaching $3.69. This growth comes as the medical technology firm rebounds from a cybersecurity incident that disrupted operations earlier this year. The U.S. organic sales increased by 9%, while international sales rose by 8.9%.
MedSurg and Neurotechnology sales grew by 9.2%, with notable increases in instruments (8.4%) and endoscopy (10.2%) within the U.S. Orthopaedics also saw an 8.6% growth. Despite a 6.7% decline in U.S. vascular sales due to operational disruptions, Stryker is optimistic about a strong second half of 2026. The company expects organic net sales growth for the full year to be between 8.3% and 9.3%.
Stryker closed its acquisition of AVS during the quarter, aiming to expand its portfolio with intravascular lithotripsy products. The firm maintains a cash balance of around $3.5 billion and generated $1.8 billion from operations this year, with plans to continue its acquisition strategy while resuming share repurchases.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
